Transduction Profiles of Recombinant Adeno-Associated Virus Vectors Derived from Serotypes 2 and 5 in the Nigrostriatal System of Rats
Open Access
- 1 July 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (13) , 6808-6817
- https://doi.org/10.1128/jvi.78.13.6808-6817.2004
Abstract
We compared the transduction efficiencies and tropisms of titer-matched recombinant adeno-associated viruses (rAAV) derived from serotypes 2 and 5 (rAAV-2 and rAAV-5, respectively) within the rat nigrostriatal system. The two serotypes (expressing enhanced green fluorescent protein [EGFP]) were delivered by stereotaxic surgery into the same animals but different hemispheres of the striatum (STR), the substantia nigra (SN), or the medial forebrain bundle (MFB). While both serotypes transduced neurons effectively within the STR, rAAV-5 resulted in a much larger EGFP-expressing area than did rAAV-2. However, neurons transduced with rAAV-2 vectors expressed higher levels of EGFP. Consistent with this result, EGFP-positive projections emanating from transduced striatal neurons covered a larger area of the SN pars reticulata (SNr) after striatal delivery of rAAV-5, but EGFP levels in fibers of the SNr were higher after striatal injection of rAAV-2. We also compared the potentials of the two vectors for retrograde transduction and found that striatal delivery of rAAV-5 resulted in significantly more transduced dopaminergic cell bodies within the SN pars compacta and ventral tegmental area. Similarly, EGFP-transduced striatal neurons were detected only after nigral delivery of rAAV-5. Furthermore, we demonstrate that after striatal AAV-5 vector delivery, the transduction profiles were stable for as long as 9 months. Finally, although we did not target the hippocampus directly, efficient and widespread transduction of hippocampal neurons was observed after delivery of rAAV-5, but not rAAV-2, into the MFB.Keywords
This publication has 50 references indexed in Scilit:
- Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapyBlood, 2003
- Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brainGene Therapy, 2003
- Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectorsGene Therapy, 2003
- Recombinant Adeno-associated Virus Serotypes 2– and 5–Mediated Gene Transfer in the Mammalian Brain: Quantitative Analysis of Heparin Co-infusionMolecular Therapy, 2002
- Adeno-Associated Virus Serotype 4 (AAV4) and AAV5 Both Require Sialic Acid Binding for Hemagglutination and Efficient Transduction but Differ in Sialic Acid Linkage SpecificityJournal of Virology, 2001
- Gene Transfer to the Nigrostriatal System by Hybrid Herpes Simplex Virus/Adeno-Associated Virus Amplicon VectorsHuman Gene Therapy, 1999
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's diseaseNature Genetics, 1998
- Mutation in the α-Synuclein Gene Identified in Families with Parkinson's DiseaseScience, 1997
- Inhibition of fast axonal transport and microtubule polymerization in vitro by colchicine and colchiceineActa Physiologica Scandinavica, 1979